Get started
Author

Sakeena Syed

ORCID: 0000-0003-3887-7521
Observed ORCID: 0000-0003-3887-7521
OpenAlex ID: A5041362936
Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma
2019 · Junling Zhuang, Fazal Shirazi, et al. · Blood · 78
Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2022 · Karen McGovern, Alfredo C. Castro, et al. · Molecular Cancer Therapeutics · 51
PDF
MEK inhibition leads to BRCA2 downregulation and sensitization to DNA damaging agents in pancreas and ovarian cancer models
2018 · Francesca Vena, Ruochen Jia, et al. · Oncotarget · 50
PDF
Abstract 2156: IK-930 is a novel TEAD inhibitor for the treatment of cancers harboring mutations in the Hippo signal transduction pathway
2022 · Benjamin S. Amidon, Marta Sanchez-Martin, et al. · Cancer Research · 20
Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma
2019 · Erin K. Willert, Garrett L. Robinson, et al. · Cancer Research · 15
Abstract P216: IK-930 mediated TEAD inhibition decreases and delays tumor growth and enhances targeted apoptosis in lung and colon cancer xenografts when combined with MEK or EGFR inhibitors
2021 · Benjamin Amidon, Hyejin Frosch, et al. · Molecular Cancer Therapeutics · 10
TAK-573, an anti-CD38-targeted attenuated interferon alpha (IFNα) fusion protein, showed anti-myeloma tumor responses in combination with standard of care (SOC) agents in multiple myeloma (MM) xenograft tumor models in vivo
2019 · Marjan Fatholahi, Miriam Valencia, et al. · Clinical Lymphoma Myeloma & Leukemia · 10
Discovery of 4-aminopyrimidine analogs as highly potent dual P70S6K/Akt inhibitors
2021 · Yufang Xiao, Bayard R. Huck, et al. · Bioorganic & Medicinal Chemistry Letters · 7
Preclinical evaluation of the CD38‐targeting engineered toxin body MT‐0169 against multiple myeloma
2024 · Wassilis S. C. Bruins, Rosa Rentenaar, et al. · HemaSphere · 5
PDF
The Anti-Tumor Effect of the Ubiquitin-Activating Enzyme (UAE) Inhibitor TAK-243 on Pre-Clinical Models of Multiple Myeloma
2016 · Junling Zhuang, Hans Lee, et al. · Blood · 5
Macrophage-targeted photodynamic detection of vulnerable atherosclerotic plaque
2003 · Michael R. Hamblin, Ahmed Tawakol, et al. · Proceedings of SPIE, the International Society for Optical Engineering/Proceedings of SPIE · 5
448 Discovery of clinical candidate IK-175, a selective orally active AHR antagonist
2020 · Karen Mcgovern, Alfredo Castro, et al. · Journal for ImmunoTherapy of Cancer · 3
CD38-targeted attenuated interferon alpha immunocytokine activates both innate and adaptive immune cells to drive anti-tumor activity
2025 · James F. Sampson, Hong Zhang, et al. · PLoS ONE · 2
PDF
De Novo Design of a Miniprotein That Functions As an Adapter for CAR-T Cells and Enables Modular Tumor Targeting for the Treatment of AML
2024 · Maria Llases, Craig McKay, et al. · Blood · 1
PDF
Abstract 2384: TAK-169, an exceptionally potent CD38 targeted engineered toxin body, as a novel direct cell kill approach for the treatment of multiple myeloma
2019 · Erin K. Willert, Garrett L. Robinson, et al. · Immunology · 1
Abstract 4516: Evaluation of p70S6K/Akt inhibitor MSC2363318A in patient derived xenograft (PDX) models of breast cancer
2014 · Bayard R. Huck, H Tian, et al. · Cancer Research · 1
Abstract 2886: A de novo designed miniprotein enables modular and specific CAR-T targeting
2025 · Maria Eugenia Llases, Craig McKay, et al. · Cancer Research
Abstract 3609: Chimeric cytokine receptors increase memory phenotypes and improve expansion and efficacy of CAR-T cell therapies
2024 · John R. Newcomb, Jun Ren, et al. · Cancer Research
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Supplementary Figure from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
PDF
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Supplementary Table from Discovery and Characterization of a Novel Aryl Hydrocarbon Receptor Inhibitor, IK-175, and Its Inhibitory Activity on Tumor Immune Suppression
2023 · Karen McGovern, Alfredo C. Castro, et al.
Works count: 34
Citation count: 264
H-index: 7
I10-index: 7
Year
Topic
Type